Osteopontin reduced hypoxia-ischemia neonatal brain injury by suppression of apoptosis in a rat pup model

Stroke

Volumn 42, Issue 3, 2011, Pages 764-769

  Chen, Wanqiu ^a   Ma, Qingyi ^a   Suzuki, Hidenori ^a   Hartman, Richard ^a   Tang, Jiping ^a   Zhang, John H ^a  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

hypoxic ischemic; neonatal; neuroprotection; osteopontin

Indexed keywords

BETA ACTIN; CASPASE 3; OSTEOPONTIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BRAIN INFARCTION SIZE; BRAIN INJURY; BRAIN ISCHEMIA; CAROTID ARTERY LIGATION; CONTROLLED STUDY; HEMISPHERE; HUMAN; MAZE TEST; NEUROLOGIC EXAMINATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RAT; STAINING; TREATMENT OUTCOME;

ANIMALS; ANIMALS, NEWBORN; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CASPASE 3; CELL DEATH; DISEASE MODELS, ANIMAL; HYPOXIA-ISCHEMIA, BRAIN; OSTEOPONTIN; RATS;

EID: 79952072254     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.110.599118     Document Type: Article

References (23)

1. Volpe JJ. Perinatal brain injury: from pathogenesis to neuroprotection. Ment Retard Dev Disabil Res Rev. 2001;7:56-64. (Pubitemid 32206303)
2. Pulera MR, Adams LM, Liu H, Santos DG, Nishimura RN, Yang F, Cole GM, Wasterlain CG. Apoptosis in a neonatal rat model of cerebral hypoxia - ischemia. Stroke. 1998;29:2622-2630. (Pubitemid 28544015)
3. Sidhu RS, Tuor UI, Del Bigio MR. Nuclear condensation and fragmentation following cerebral hypoxia - ischemia occurs more frequently in immature than older rats. Neurosci Lett. 1997;223:129-132. (Pubitemid 27112793)
4. Manabat C, Han BH, Wendland M, Derugin N, Fox CK, Choi J, Holtzman DM, Ferriero DM, Vexler ZS. Reperfusion differentially induces caspase-3 activation in ischemic core and penumbra after stroke in immature brain. Stroke. 2003;34:207-213. (Pubitemid 36070825)
5. Mazzali M, Kipari T, Ophascharoensuk V, Wesson JA, Johnson R, Hughes J. Osteopontin-a molecule for all seasons. QJM. 2002;95:3-13. (Pubitemid 34173287)
6. Song G, Cai QF, Mao YB, Ming YL, Bao SD, Ouyang GL. Osteopontin promotes ovarian cancer progression and cell survival and increases HIF-1alpha expression through the PI3-K/Akt pathway. Cancer Sci. 2008;99:1901-1907.
7. Huang H, Zhang XF, Zhou HJ, Xue YH, Dong QZ, Ye QH, Qin LX. Expression and prognostic significance of osteopontin and caspase-3 in hepatocellular carcinoma patients after curative resection. Cancer Sci. 2010;101:1314-1319.
8. Meller R, Stevens SL, Minami M, Cameron JA, King S, Rosenzweig H, Doyle K, Lessov NS, Simon RP, Stenzel-Poore MP. Neuroprotection by osteopontin in stroke. J Cereb Blood Flow Metab. 2005;25:217-225. (Pubitemid 40171203)
9. Persy VP, Verhulst A, Ysebaert DK, De Greef KE, De Broe ME. Reduced postischemic macrophage infiltration and interstitial fibrosis in osteopontin knockout mice. Kidney Int. 2003;63:543-553. (Pubitemid 36126800)
10. Rice JE III, Vannucci RC, Brierley JB. The influence of immaturity on hypoxic-ischemic brain damage in the rat. Ann Neurol. 1981;9:131-141. (Pubitemid 11191192)
11. Chen W, Hartman R, Ayer R, Marcantonio S, Kamper J, Tang J, Zhang JH. Matrix metalloproteinases inhibition provides neuroprotection against hypoxia - ischemia in the developing brain. J Neurochem. 2009;111:726-736.
12. Suzuki H, Ayer R, Sugawara T, Chen W, Sozen T, Hasegawa Y, Kanamaru K, Zhang JH. Protective effects of recombinant osteopontin on early brain injury after subarachnoid hemorrhage in rats. Crit Care Med. 2010;38:612-618.
13. Cai Z, Pang Y, Lin S, Rhodes PG. Differential roles of tumor necrosis factor-alpha and interleukin-1 beta in lipopolysaccharide-induced brain injury in the neonatal rat. Brain Res. 2003;975:37-47. (Pubitemid 36588550)
14. Sugawara T, Jadhav V, Ayer R, Chen W, Suzuki H, Zhang JH. Thrombin inhibition by argatroban ameliorates early brain injury and improves neurological outcomes after experimental subarachnoid hemorrhage in rats. Stroke. 2009;40:1530-1532.
15. Gonzalez FF, Ferriero DM. Therapeutics for neonatal brain injury. Pharmacol Ther. 2008;120:43-53.
16. Butler WT. The nature and significance of osteopontin. Connect Tissue Res. 1989;23:123-136.
17. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA. Integrin alpha V beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994;79:1157-1164.
18. Takano S, Tsuboi K, Tomono Y, Mitsui Y, Nose T. Tissue factor, osteopontin, alphavbeta3 integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression. Br J Cancer. 2000;82:1967-1973. (Pubitemid 30326458)
19. Vosler PS, Chen J. Potential molecular targets for translational stroke research. Stroke. 2009;40:S119-120.
20. Rothman SM, Olney JW. Glutamate and the pathophysiology of hypoxicischemic brain damage. Ann Neurol. 1986;19:105-111. (Pubitemid 16114163)
21. Raff MC, Barres BA, Burne JF, Coles HS, Ishizaki Y, Jacobson MD. Programmed cell death and the control of cell survival: lessons from the nervous system. Science. 1993;262:695-700. (Pubitemid 23350688)
22. Zhang A, Liu Y, Shen Y, Xu Y, Li X. Osteopontin silencing by small interfering RNA induces apoptosis and suppresses invasion in human renal carcinoma Caki-1 cells. Med Oncol. 2010;27:1179-1184.
23. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest. 2001;107:1055-1061. (Pubitemid 32422899)